Futuretech II Acquisition Faces Mounting Challenges

Futuretech II SPAC's merger with Longevity Biomedical stalls due to governance issues, a 'going concern' warning, and missed deadlines, casting doubt on the deal's completion.

The proposed merger between Futuretech II Acquisition Corp. and Longevity Biomedical is encountering significant obstacles, casting doubt on the transaction's completion. The Special Purpose Acquisition Company (SPAC) is now grappling with a combination of internal governance issues and pressing financial concerns, leaving investors anxious for clarity on its path forward.

Governance and Financial Stability in Question

Confidence in Futuretech II has been undermined by a series of compliance problems. The company has faced pressure due to delayed quarterly reports and breaches of rules governing publicly held shares. A critical development was the resignation of its auditor, followed two months ago in January by the publication of a "going concern" warning, expressing substantial doubt about the company's ability to continue operating. These events raise serious questions about the firm's foundational stability and its capacity to successfully integrate with a target company post-merger.

For the deal to proceed, management is under intense pressure to promptly file the outstanding financial statements and demonstrate compliance with Nasdaq listing standards. The original timeline for taking the combined entity public has already lapsed.

Merger with Longevity Biomedical Stalls

The path to combining with Longevity Biomedical, first announced in September 2024, has been slow and arduous. Despite a revised agreement in August 2025 and ongoing regulatory submissions, the transaction remains unfinished. Initial projections aimed for a closing in the fourth quarter of 2025.

The strategic goal of the merger is to list on the Nasdaq under the Longevity Biomedical name, focusing on technologies aimed at extending and improving human health. However, before this new chapter can begin, several pending closing conditions and necessary regulatory approvals must be satisfied. The central question for stakeholders is whether management can navigate these regulatory hurdles and rectify its operational deficits in time to salvage the deal.

The immediate priority for Futuretech II's leadership is to provide a firm and credible closing date. The company's future hinges on its ability to swiftly address these compounded challenges of internal governance, financial reporting, and merger execution.